BEAMX / TRY

BEAMX / USDT

BEAMX / USDC

GALA / BTC

TUT / USDC

TUT / USDT

IOTX / BTC

IMX / BTC

PHA / BTC

IMX / USDT

HOME / BNB

LA / BNB

W / BTC

W / TRY

W / USDT

PEOPLE / BTC

W / USDC

W / FDUSD

BIO / BNB

LA / USDC

SNEHAA ORGANICS LIMITED

INTENSE TECHNOLOGIES LTD

ADANI TOTAL GAS LIMITED

MASK INVESTMENTS LIMITED

ADANI POWER LTD

STL NETWORKS LIMITED

RAMKY INFRA LTD

CAREER POINT EDUTECH LTD

DIGIKORE STUDIOS LIMITED

VIP CLOTHING LIMITED

TOURISM FINANCE CORP. OF

SARVESHWAR FOODS LIMITED

OSIA HYPER RETAIL LIMITED

S.A.L. STEEL LTD.

DREAMFOLKS SERVICES LTD

TEERTH GOPICON LIMITED

DUCOL ORGS AND COLOURS LT

DEV ACCELERATOR LIMITED

ASHOKA METCAST LIMITED

IRM ENERGY LIMITED

Click here to get full coverage on Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update - NeurologyLive

Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update  NeurologyLive

Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update - NeurologyLive

Click here to get full coverage on Zota Health Care to Engage with Investors at Mumbai Conference - TipRanks

Zota Health Care to Engage with Investors at Mumbai Conference  TipRanks

Zota Health Care to Engage with Investors at Mumbai Conference - TipRanks

Click here to get full coverage on Patients With DMD Treated With Avidity Biosciences’ Antibody-Oligonucleotide Conjugate Del-Zota Show Functional Improvements - CGTLive®

Patients With DMD Treated With Avidity Biosciences’ Antibody-Oligonucleotide Conjugate Del-Zota Show Functional Improvements  CGTLive®

Patients With DMD Treated With Avidity Biosciences’ Antibody-Oligonucleotide Conjugate Del-Zota Show Functional Improvements - CGTLive®

Click here to get full coverage on Suspected gunman accused in 2017 double murder at Longboat Key’s Zota Beach Resort charged - FOX 13 Tampa Bay

Suspected gunman accused in 2017 double murder at Longboat Key’s Zota Beach Resort charged  FOX 13 Tampa Bay

Suspected gunman accused in 2017 double murder at Longboat Key’s Zota Beach Resort charged - FOX 13 Tampa Bay

Click here to get full coverage on Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients - Clinical Trials Arena

Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients  Clinical Trials Arena

Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients - Clinical Trials Arena

Click here to get full coverage on Gunman in Longboat Key Zota murders arrested after 2017 shooting, police say - Bradenton Herald

Gunman in Longboat Key Zota murders arrested after 2017 shooting, police say  Bradenton Herald

Gunman in Longboat Key Zota murders arrested after 2017 shooting, police say - Bradenton Herald

Click here to get full coverage on Third suspect charged in 2017 Zota Beach Resort double-homicide - ABC7 WWSB

Third suspect charged in 2017 Zota Beach Resort double-homicide  ABC7 WWSB

Third suspect charged in 2017 Zota Beach Resort double-homicide - ABC7 WWSB

Click here to get full coverage on Del-zota for DMD awarded FDA breakthrough therapy designation - Muscular Dystrophy News

Del-zota for DMD awarded FDA breakthrough therapy designation  Muscular Dystrophy News

Del-zota for DMD awarded FDA breakthrough therapy designation - Muscular Dystrophy News

Click here to get full coverage on Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44 - Yahoo Finance

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44  Yahoo Finance

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44 - Yahoo Finance

Click here to get full coverage on Zota Health Care Reaches All-Time High, Signaling Strong Market Confidence in Sector - Markets Mojo

Zota Health Care Reaches All-Time High, Signaling Strong Market Confidence in Sector  Markets Mojo

Zota Health Care Reaches All-Time High, Signaling Strong Market Confidence in Sector - Markets Mojo

Click here to get full coverage on Avidity Biosciences reports positive one-year data for del-zota in DMD44 trials - Drug Discovery News

Avidity Biosciences reports positive one-year data for del-zota in DMD44 trials  Drug Discovery News

Avidity Biosciences reports positive one-year data for del-zota in DMD44 trials - Drug Discovery News

Click here to get full coverage on Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota - Seeking Alpha

Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota  Seeking Alpha

Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota - Seeking Alpha

Click here to get full coverage on Zota Beach Resort sets the scene for local business connections - Your Observer

Zota Beach Resort sets the scene for local business connections  Your Observer

Zota Beach Resort sets the scene for local business connections - Your Observer

Click here to get full coverage on Suspect arrested in 2017 Zota Beach Resort double murder - WFLA

Suspect arrested in 2017 Zota Beach Resort double murder  WFLA

Suspect arrested in 2017 Zota Beach Resort double murder - WFLA

Click here to get full coverage on Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA - BioSpace

Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA  BioSpace

Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA - BioSpace

Click here to get full coverage on Mechanism and Promise Behind Del-Zota for Duchenne Muscular Dystrophy: Michael Flanagan, PhD - NeurologyLive

Mechanism and Promise Behind Del-Zota for Duchenne Muscular Dystrophy: Michael Flanagan, PhD  NeurologyLive

Mechanism and Promise Behind Del-Zota for Duchenne Muscular Dystrophy: Michael Flanagan, PhD - NeurologyLive

Click here to get full coverage on Del-Zota for Duchenne Muscular Dystrophy - CGTLive®

Del-Zota for Duchenne Muscular Dystrophy  CGTLive®

Del-Zota for Duchenne Muscular Dystrophy - CGTLive®

Click here to get full coverage on One more suspect charged in 2017 Longboat Key homicide case - Your Observer

One more suspect charged in 2017 Longboat Key homicide case  Your Observer

One more suspect charged in 2017 Longboat Key homicide case - Your Observer

Click here to get full coverage on Cantor finds Avidity data highly supportive of del-zota best-in-class potential - TipRanks

Cantor finds Avidity data highly supportive of del-zota best-in-class potential  TipRanks

Cantor finds Avidity data highly supportive of del-zota best-in-class potential - TipRanks

Click here to get full coverage on Michael Flanagan, PhD, on Del-zota’s Breakthrough Potential for Duchenne Muscular Dystrophy - NeurologyLive

Michael Flanagan, PhD, on Del-zota’s Breakthrough Potential for Duchenne Muscular Dystrophy  NeurologyLive

Michael Flanagan, PhD, on Del-zota’s Breakthrough Potential for Duchenne Muscular Dystrophy - NeurologyLive

Click here to get full coverage on Avidity del-zota data ‘highly encouraging,’ says Cantor Fitzgerald - TipRanks

Avidity del-zota data ‘highly encouraging,’ says Cantor Fitzgerald  TipRanks

Avidity del-zota data ‘highly encouraging,’ says Cantor Fitzgerald - TipRanks

Click here to get full coverage on Zota Health Care Limited's (NSE:ZOTA) market cap increased by ₹5.2b, insiders receive a 58% cut - simplywall.st

Zota Health Care Limited's (NSE:ZOTA) market cap increased by ₹5.2b, insiders receive a 58% cut  simplywall.st

Zota Health Care Limited's (NSE:ZOTA) market cap increased by ₹5.2b, insiders receive a 58% cut - simplywall.st

Click here to get full coverage on Avidity Biosciences’ Del-Zota Shows Promising Data in DMD, Justifying Buy Rating and $56 Price Target - TipRanks

Avidity Biosciences’ Del-Zota Shows Promising Data in DMD, Justifying Buy Rating and $56 Price Target  TipRanks

Avidity Biosciences’ Del-Zota Shows Promising Data in DMD, Justifying Buy Rating and $56 Price Target - TipRanks

Click here to get full coverage on Man arrested 8 years after double homicide at Longboat Key resort - wtsp.com

Man arrested 8 years after double homicide at Longboat Key resort  wtsp.com

Man arrested 8 years after double homicide at Longboat Key resort - wtsp.com

Click here to get full coverage on Avidity Biosciences: Promising Outlook for DMD Treatment with Del-Zota and Platform Expansion - TipRanks

Avidity Biosciences: Promising Outlook for DMD Treatment with Del-Zota and Platform Expansion  TipRanks

Avidity Biosciences: Promising Outlook for DMD Treatment with Del-Zota and Platform Expansion - TipRanks

Click here to get full coverage on 25% Dystrophin Increase & 80% CK Reduction: Avidity's Del-zota Achieves Breakthrough in DMD44 Treatment - Stock Titan

25% Dystrophin Increase & 80% CK Reduction: Avidity's Del-zota Achieves Breakthrough in DMD44 Treatment  Stock Titan

25% Dystrophin Increase & 80% CK Reduction: Avidity's Del-zota Achieves Breakthrough in DMD44 Treatment - Stock Titan

Click here to get full coverage on Avidity stock rises after del-zota shows disease reversal in DMD44 trial - Investing.com

Avidity stock rises after del-zota shows disease reversal in DMD44 trial  Investing.com

Avidity stock rises after del-zota shows disease reversal in DMD44 trial - Investing.com

Click here to get full coverage on Zota Health Care Achieves All-Time High, Signaling Strong Growth in Pharmaceuticals Sector - Markets Mojo

Zota Health Care Achieves All-Time High, Signaling Strong Growth in Pharmaceuticals Sector  Markets Mojo

Zota Health Care Achieves All-Time High, Signaling Strong Growth in Pharmaceuticals Sector - Markets Mojo

Click here to get full coverage on Michael Flanagan, PhD, on Del-Zota for Duchenne Muscular Dystrophy - CGTLive®

Michael Flanagan, PhD, on Del-Zota for Duchenne Muscular Dystrophy  CGTLive®

Michael Flanagan, PhD, on Del-Zota for Duchenne Muscular Dystrophy - CGTLive®

Click here to get full coverage on Avidity Biosciences' del-zota shows disease reversal in key endpoints - MarketScreener

Avidity Biosciences' del-zota shows disease reversal in key endpoints  MarketScreener

Avidity Biosciences' del-zota shows disease reversal in key endpoints - MarketScreener

Click here to get full coverage on Avidity's exon-skipping therapy shows dystrophin gains in Duchenne trial update - FirstWord Pharma

Avidity's exon-skipping therapy shows dystrophin gains in Duchenne trial update  FirstWord Pharma

Avidity's exon-skipping therapy shows dystrophin gains in Duchenne trial update - FirstWord Pharma

Click here to get full coverage on Zota Health Care Reaches All-Time High, Signaling Strong Sector Performance and Growth Potential - Markets Mojo

Zota Health Care Reaches All-Time High, Signaling Strong Sector Performance and Growth Potential  Markets Mojo

Zota Health Care Reaches All-Time High, Signaling Strong Sector Performance and Growth Potential - Markets Mojo

Click here to get full coverage on Zota Health Care Reaches All-Time High, Signaling Strong Market Momentum - Markets Mojo

Zota Health Care Reaches All-Time High, Signaling Strong Market Momentum  Markets Mojo

Zota Health Care Reaches All-Time High, Signaling Strong Market Momentum - Markets Mojo

Click here to get full coverage on Zota Health Care expands Davaindia network to 1,760 operational stores - Indian Pharma Post

Zota Health Care expands Davaindia network to 1,760 operational stores  Indian Pharma Post

Zota Health Care expands Davaindia network to 1,760 operational stores - Indian Pharma Post

Click here to get full coverage on Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - BioSpace

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping  BioSpace

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - BioSpace

Click here to get full coverage on Avidity stock rises after del-zota shows disease reversal in DMD44 trial - Investing.com Nigeria

Avidity stock rises after del-zota shows disease reversal in DMD44 trial  Investing.com Nigeria

Avidity stock rises after del-zota shows disease reversal in DMD44 trial - Investing.com Nigeria

Click here to get full coverage on Avidity's latest DMD data drop assuages safety concerns for RNA-based asset: analyst - Fierce Biotech

Avidity's latest DMD data drop assuages safety concerns for RNA-based asset: analyst  Fierce Biotech

Avidity's latest DMD data drop assuages safety concerns for RNA-based asset: analyst - Fierce Biotech

Click here to get full coverage on Promising Early Results of Investigational Duchenne Muscular Dystrophy Therapy - Managed Healthcare Executive

Promising Early Results of Investigational Duchenne Muscular Dystrophy Therapy  Managed Healthcare Executive

Promising Early Results of Investigational Duchenne Muscular Dystrophy Therapy - Managed Healthcare Executive

Click here to get full coverage on Investors Interested In Zota Health Care Limited's (NSE:ZOTA) Revenues - simplywall.st

Investors Interested In Zota Health Care Limited's (NSE:ZOTA) Revenues  simplywall.st

Investors Interested In Zota Health Care Limited's (NSE:ZOTA) Revenues - simplywall.st

Click here to get full coverage on Zota Health Care expands Davaindia network to 1,530 stores - Indian Pharma Post

Zota Health Care expands Davaindia network to 1,530 stores  Indian Pharma Post

Zota Health Care expands Davaindia network to 1,530 stores - Indian Pharma Post

Click here to get full coverage on Zota Health Care expands Davaindia Network to 1,413 operational stores - Indian Pharma Post

Zota Health Care expands Davaindia Network to 1,413 operational stores  Indian Pharma Post

Zota Health Care expands Davaindia Network to 1,413 operational stores - Indian Pharma Post

Click here to get full coverage on Zota Health Care board approves ₹500-crore fundraise via equity route - CNBC TV18

Zota Health Care board approves ₹500-crore fundraise via equity route  CNBC TV18

Zota Health Care board approves ₹500-crore fundraise via equity route - CNBC TV18

Click here to get full coverage on Zota Health Care Achieves All-Time High Amid Strong Market Momentum - Markets Mojo

Zota Health Care Achieves All-Time High Amid Strong Market Momentum  Markets Mojo

Zota Health Care Achieves All-Time High Amid Strong Market Momentum - Markets Mojo

Click here to get full coverage on Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 - BioSpace

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025  BioSpace

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 - BioSpace

Click here to get full coverage on Novartis Continues Hunt for New Assets With Rumored Takeover of RNA Specialist Avidity - BioSpace

Novartis Continues Hunt for New Assets With Rumored Takeover of RNA Specialist Avidity  BioSpace

Novartis Continues Hunt for New Assets With Rumored Takeover of RNA Specialist Avidity - BioSpace

Click here to get full coverage on Zota Health Care Achieves All-Time High, Signaling Strong Market Performance and Growth Potential - Markets Mojo

Zota Health Care Achieves All-Time High, Signaling Strong Market Performance and Growth Potential  Markets Mojo

Zota Health Care Achieves All-Time High, Signaling Strong Market Performance and Growth Potential - Markets Mojo

Click here to get full coverage on Zota Health Care Achieves All-Time High, Signaling Strong Market Momentum - Markets Mojo

Zota Health Care Achieves All-Time High, Signaling Strong Market Momentum  Markets Mojo

Zota Health Care Achieves All-Time High, Signaling Strong Market Momentum - Markets Mojo

Click here to get full coverage on Behind the castle gates: Florida sand sculptor gives a glimpse of his craft - Your Observer

Behind the castle gates: Florida sand sculptor gives a glimpse of his craft  Your Observer

Behind the castle gates: Florida sand sculptor gives a glimpse of his craft - Your Observer

Click here to get full coverage on Consumers are now actively seeking generic substitutes for branded medicines: Sujit Paul, Zota Healthcare - The Economic Times

Consumers are now actively seeking generic substitutes for branded medicines: Sujit Paul, Zota Healthcare  The Economic Times

Consumers are now actively seeking generic substitutes for branded medicines: Sujit Paul, Zota Healthcare - The Economic Times

Click here to get full coverage on Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - BioSpace

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference  BioSpace

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - BioSpace

Click here to get full coverage on Zota Health Care Stock Reaches All-Time High, Signaling Strong Market Momentum - Markets Mojo

Zota Health Care Stock Reaches All-Time High, Signaling Strong Market Momentum  Markets Mojo

Zota Health Care Stock Reaches All-Time High, Signaling Strong Market Momentum - Markets Mojo

Click here to get full coverage on Zota Health Care (NSE:ZOTA) surges 24% this week, taking five-year gains to 460% - simplywall.st

Zota Health Care (NSE:ZOTA) surges 24% this week, taking five-year gains to 460%  simplywall.st

Zota Health Care (NSE:ZOTA) surges 24% this week, taking five-year gains to 460% - simplywall.st

Click here to get full coverage on Del-zota increases dystrophin in DMD patients, new trial data show - Muscular Dystrophy News

Del-zota increases dystrophin in DMD patients, new trial data show  Muscular Dystrophy News

Del-zota increases dystrophin in DMD patients, new trial data show - Muscular Dystrophy News

Click here to get full coverage on Zota Health Care Achieves Record Stock Price Amid Strong Sector Performance - Markets Mojo

Zota Health Care Achieves Record Stock Price Amid Strong Sector Performance  Markets Mojo

Zota Health Care LImited (ZOTA)

Price Chart

Key Statistics

Technicals

About ZOTA

Latest News

Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update - NeurologyLive

Zota Health Care to Engage with Investors at Mumbai Conference - TipRanks

Patients With DMD Treated With Avidity Biosciences’ Antibody-Oligonucleotide Conjugate Del-Zota Show Functional Improvements - CGTLive®

Advanced Charts

Top Gainers

Top Losers